Urodynamic Feasibility Study Utilizing the UroLift® System

Inclusion Criteria: * Male gender * Diagnosis of symptomatic BPH * Age ≥ 45 years * International Prostate Symptom Score (IPSS) ≥ 13 * Peak urine flow rate ≤ 12 ml/sec, voided volume ≥ 125 ml * Prostate volume ≤ 80 cc per ultrasound Exclusion Criteria: * Current urinary retention * Post void residual (PVR) urine \> 250 ml * Have an obstructive or protruding median lobe of the prostate * Active urinary tract infection at time of treatment * Current gross hematuria * Previous BPH surgical procedure * Previous pelvic surgery or irradiation * History of neurogenic or atonic bladder * Stress urinary incontinence * Biopsy of the prostate within the past 6 weeks * Life expectancy estimated to be less than 1 year * History of prostate or bladder cancer * Elevated Prostate-Specific Antigen (PSA) without ruling out prostate cancer * History of compromised renal function or upper tract disease * Known coagulopathies or subject on anticoagulants or antiplatelets other than aspirin ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure) * Use of the following medications pre-screening (uroflow, questionnaires): * Within 4 months of baseline assessment: estrogen, any drug producing androgen suppression, or anabolic steroids * Within 3 months of baseline assessment: 5-alpha-reductase inhibitors * Within 2 weeks of baseline assessment: alpha-blockers, gonadotropin-releasing hormonal analogs, anticholinergics or cholinergic medication or phenylephrine, pseudoephedrine, or imipramine medications * Within 1 week of baseline assessment, unless documented on stable dose for ≥ 6 months: beta blockers, antidepressants, anticonvulsants, and antispasmodics * Cystolithiasis within the prior 3 months * History of co-morbidities that would affect having an elective urological procedure including: prostatitis, conditions that preclude the insertion of the UroLift System. * Other co-morbidities that could impact the study results such as: * Severe cardiac arrhythmias uncontrolled by medications or pacemaker * Congestive heart failure New York Heart Assocation (NYHA) III or IV * History of uncontrolled diabetes mellitus * Significant respiratory disease in which hospitalization may be required * Known immunosuppression (i.e. AIDS, post-transplant, undergoing chemotherapy) * A known allergy to nickel, titanium, or stainless steel * Unable or unwilling to complete all required questionnaires and follow up assessments * Unable or unwilling to sign informed consent form * Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint.